CTRI/2024/03/063691尚未招募3 期
A Multicentric, Randomized, Double Blind, Double Dummy, Active Controlled, Prospective, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Pregabalin, Duloxetine (As Gastro Resistant Pellets) and Mecobalamin Capsules Versus Fixed Dose Combination of Pregabalin, Nortriptyline and Mecobalamin Tablets for the Treatment of Patients with Diabetic Peripheral Neuropathic Pain with Coexistent Vitamin B12 Deficiency. - NI
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients aged between 18 and 65 years (both inclusive).
- •2. Patients with documented diagnosis of type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) levels less than or equal to 11% and having pain associated with diabetic peripheral neuropathy for more than or equal to 6 months.
- •3. Patients who experience pain associated with diabetic peripheral neuropathy and having visual analogue scale (VAS) score more than or equal to 30 at screening and baseline visit.
- •4. Patients with decreased vitamin B12 levels (less than 200 pg per mL) at screening visit.
- •5. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening or baseline visit.
- •6. Patient with ability to understand and provide written, signed and dated informed consent form, which must have been obtained prior to screening.
- •7. Patients willing to comply with all the protocol requirements.
排除标准
- •1. Patients with history of hypersensitivity to either of the study medication or related class of drugs.
- •2. Patients with prior therapy with Pregabalin or Duloxetine or Nortriptyline and having any other neurologic disorders unrelated to diabetic peripheral neuropathic pain were excluded.
- •3. Patients who are experiencing non-diabetic peripheral neuropathy-related pain.
- •4. Patients with clinically significant impaired hepatic function (SGOT & SGPT more than 3X the UNL and or Total bilirubin more than 1.5X the UNL) at screening.
- •5. Patients with clinically significant impaired renal function (Serum creatinine more than 1.5X the ULN) at screening.
- •6. Patients having serum sodium level less than 130 mmol per L at screening.
- •7. Patients with history of type 1 diabetes mellitus.
- •8. Patients with uncontrolled hypertension with sitting systolic BP more than or equal to 160 mmHg and or diastolic BP more than or equal to 100 mmHg at screening.
- •9. Patients with any abnormality on 12-lead ECG at screening that in the opinion of the investigator is clinically significant and is judged as potential risk for patient’s participation in the study.
- •10. Patients with history of suicidal thoughts and behavior.
- •11. Patients with history of clinically significant medical illness in past 3 months, such as cardiovascular disease (e.g., MI, uncontrolled hypertension, orthostatic hypotension), falls and syncope, central nervous system diseases (e.g., seizure, bipolar disorder, depression, generalized anxiety disorder), liver disease, angioedema, peripheral edema, angle-closure glaucoma, urinary retention, bleeding disorder or any other disorder which may compromise safety of patient as per investigator discretion.
- •12. Patients treated with drugs that impair metabolism of serotonin (mono-amine oxidase inhibitors, Linezolide, Methylene Blue) or serotonergic agents other than study drugs (SSRIs, SNRIs, triptans, antidepressants, Fentanyl, Lithium, Tramadol, Tryptophan, Buspirone, amphetamines) or corticosteroids within past 4 weeks prior to screening.
- •13. Patient treated with topical or systemic pain medications (e.g., NSAIDs, local anesthetics, Methyl Salicylate, Capsaicin, Tramadol, Tapentadol etc.) within past 2 weeks prior to baseline.
- •14. Female patients who are pregnant or breast-feeding or expecting to conceive within the projected duration of the study.
- •15. Female patients who are of childbearing potential and who are neither surgically sterilized nor willing to use reliable contraceptive methods (like hormonal, barrier methods or intrauterine device).
- •16. Patients with a history of any malignancy.
- •17. Patients with history of infection with hepatitis B, hepatitis C or HIV.
- •18. Patients with a history of substance abuse or dependence that in the opinion of the Investigator is considered to interfere with the patient’s participation in the study.
- •19. Patients with any psychiatric or mental disease compromise the ability to give the consent for participation in the study.
- •20. Patients with concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.
- •21. Patients currently taking any of the prohibited medications(s) and inability or unwillingness to discontinue them for the entire study period.
- •22. Patients with suspected inability or unwillingn
研究者
相似试验
尚未招募
3 期
A Multicentric Randomized Double Blind Double Dummy Parallel Group Comparative Phase III Clinical Study to Evaluate the Efficacy Safety and Tolerability in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).CTRI/2022/11/047055Ajanta Pharma Limited
招募中
3 期
Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.CTRI/2024/01/062147Ravenbhel Healthcare Pvt. Ltd.
尚未招募
3 期
A clinical study to see the effect and safety of Fixed Dose Combination of Silodosin and Solifenacin Capsules in Comparison to Silodosin Capsules in Male Patients Having Benign Prostatic Hyperplasia (BPH)/ Lower Urinary Tract Symptoms (LUTS) with Over Active Bladder (OAB)CTRI/2020/07/026419Sun Pharma Laboratories Limited
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Azilsartan and Amlodipine Tablets in patients with hypertension.CTRI/2022/02/040081Inventia Healthcare Ltd309
已完成
3 期
A clinical study to assess the efficacy and safety of Imeglimin Tablets in patients with diabetes.CTRI/2022/02/040348Exemed Pharmaceuticals216